Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals

Abstract

In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara—Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that is authorized and in use as a vaccine against MPX. To date, there are no data showing MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals nor vaccine efficacy against MPX. Here we show that MPXV-neutralizing antibodies can be detected after MPXV infection and after historic smallpox vaccination. However, a two-shot MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV-neutralizing antibodies. Dose-sparing of an MVA-based influenza vaccine leads to lower MPXV-neutralizing antibody levels, whereas a third vaccination with the same MVA-based vaccine significantly boosts the antibody response. As the role of MPXV-neutralizing antibodies as a correlate of protection against disease and transmissibility is currently unclear, we conclude that cohort studies following vaccinated individuals are necessary to assess vaccine efficacy in at-risk populations.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 19

1. 1.

   Thornhill JP, et al. Monkeypox virus infection in humans across 16 countries—April–June 2022. N. Engl. J. Med. 2022;387:679-691.

   Not in our library10.1056/nejmoa2207323

2. 2.

   Wenham, C. & Eccleston-Turner, M. Monkeypox as a PHEIC: implications for global health governance. Lancet (2022).

   Not in our library10.1016/s0140-6736(22)01437-4

3. 3.

   Paran N, Sutter G. Smallpox vaccines: new formulations and revised strategies for vaccination. Hum. Vaccin. 2009;5:824-831.

   Not in our library10.4161/hv.10295

4. 4.

   Volz A, Sutter G. Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. Adv. Virus Res. 2017;97:187-243.

   Not in our library10.1016/bs.aivir.2016.07.001

5. 5.

   Pittman PR, et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox. N. Engl. J. Med. 2019;381:1897-1908.

   Not in our library10.1056/nejmoa1817307

6. 6.

   Jezek Z, Grab B, Szczeniowski MV, Paluku KM, Mutombo M. Human monkeypox: secondary attack rates. Bull. World Health Organ. 1988;66:465-470.

   Not in our library

7. 7.

   Earl PL, et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 2004;428:182-185.

   Not in our library10.1038/nature02331

8. 8.

   Earl PL, et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc. Natl Acad. Sci. USA. 2008;105:10889-10894.

   Not in our library10.1073/pnas.0804985105

9. 9.

   Stittelaar KJ, et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 2005;79:7845-7851.

   Not in our library10.1128/jvi.79.12.7845-7851.2005

10. 10.

    Kupferschmidt K. Scientists scramble to set up monkeypox vaccine trials. Science. 2022;377:696-697.

    Not in our library10.1126/science.ade3371

11. 11.

    Townsend MB, et al. Humoral immunity to smallpox vaccines and monkeypox virus challenge: proteomic assessment and clinical correlations. J. Virol. 2013;87:900-911.

    Not in our library10.1128/jvi.02089-12

12. 12.

    Manischewitz J, et al. Development of a novel vaccinia-neutralization assay based on reporter-gene expression. J. Infect. Dis. 2003;188:440-448.

    Not in our library10.1086/376557

13. 13.

    Kreijtz JH, et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect. Dis. 2014;14:1196-1207.

    Not in our library10.1016/s1473-3099(14)70963-6

14. 14.

    Hammarlund E, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat. Med. 2005;11:1005-1011.

    Not in our library10.1038/nm1273

15. 15.

    Taub DD, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am. J. Med. 2008;121:1058-1064.

    Not in our library10.1016/j.amjmed.2008.08.019

16. 16.

    Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 2002;83:2915-2931.

    Not in our library10.1099/0022-1317-83-12-2915

17. 17.

    Edghill-Smith Y, et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 2005;11:740-747.

    Not in our library10.1038/nm1261

18. 18.

    Kremer M, et al. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol. Biol. 2012;890:59-92.

    Not in our library10.1007/978-1-61779-876-4_4

19. 19.

    Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991;72:1031-1038.

    Not in our library10.1099/0022-1317-72-5-1031

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.